{"id":877,"date":"2004-07-01T12:00:00","date_gmt":"2004-07-01T10:00:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2004\/kombinationstherapie-der-rheumatoiden-arthritis-mit-methotrexat-plus-etanercept"},"modified":"2004-07-01T12:00:00","modified_gmt":"2004-07-01T10:00:00","slug":"kombinationstherapie-der-rheumatoiden-arthritis-mit-methotrexat-plus-etanercept","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2004\/kombinationstherapie-der-rheumatoiden-arthritis-mit-methotrexat-plus-etanercept","title":{"rendered":"Kombinationstherapie der Rheumatoiden Arthritis mit Methotrexat plus Etanercept"},"content":{"rendered":"<p>Bei der Behandlung der Rheumatoiden Arthritis (RA) unterscheidet man zwischen der symptomatischen Therapie, z.B. mit nichtsteroidalen Antirheumatika (NSAID), und der Basistherapie (Disease modifying therapy), mit der die inflammatorische Aktivit\u00e4t der Erkrankung und der destruktive Verlauf an den Gelenken vermindert bzw. retardiert werden soll. Fr\u00fchere Studien ergaben, da\u00df Antagonisten des Tumor-Nekrose-Faktors alpha (TNF alpha, z.B. Infliximab, [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bei der Behandlung der Rheumatoiden Arthritis (RA) unterscheidet man zwischen der symptomatischen Therapie, z.B. mit nichtsteroidalen Antirheumatika (NSAID), und der Basistherapie (Disease modifying therapy), mit der die inflammatorische Aktivit\u00e4t der Erkrankung und der destruktive Verlauf an den Gelenken vermindert bzw. retardiert werden soll. Fr\u00fchere Studien ergaben, da\u00df Antagonisten des Tumor-Nekrose-Faktors alpha (TNF alpha, z.B. Infliximab, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1891,276,1067,2277],"class_list":["post-877","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-etanercept","tag-methotrexat","tag-rheumatoide-arthritis","tag-tempo-studie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/877","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=877"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/877\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=877"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=877"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}